MD20140091A2 - Terapie combinată cuprinzând hemifumarat tenofovir alafenamidă şi cobicistat pentru utilizare în tratamentul infecţiilor virale - Google Patents
Terapie combinată cuprinzând hemifumarat tenofovir alafenamidă şi cobicistat pentru utilizare în tratamentul infecţiilor virale Download PDFInfo
- Publication number
- MD20140091A2 MD20140091A2 MDA20140091A MD20140091A MD20140091A2 MD 20140091 A2 MD20140091 A2 MD 20140091A2 MD A20140091 A MDA20140091 A MD A20140091A MD 20140091 A MD20140091 A MD 20140091A MD 20140091 A2 MD20140091 A2 MD 20140091A2
- Authority
- MD
- Moldova
- Prior art keywords
- cobicistat
- tenofovir alafenamide
- alafenamide hemifumarate
- treatment
- viral infections
- Prior art date
Links
- ZCIGNRJZKPOIKD-CQXVEOKZSA-N cobicistat Chemical compound S1C(C(C)C)=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SC=NC=2)CC=2C=CC=CC=2)=C1 ZCIGNRJZKPOIKD-CQXVEOKZSA-N 0.000 title abstract 4
- 229960002402 cobicistat Drugs 0.000 title abstract 4
- SVUJNSGGPUCLQZ-FQQAACOVSA-N tenofovir alafenamide fumarate Chemical compound OC(=O)\C=C\C(O)=O.O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1.O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1 SVUJNSGGPUCLQZ-FQQAACOVSA-N 0.000 title abstract 4
- 208000036142 Viral infection Diseases 0.000 title abstract 2
- 230000009385 viral infection Effects 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 abstract 2
- 229960000366 emtricitabine Drugs 0.000 abstract 2
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 abstract 1
- 229960005107 darunavir Drugs 0.000 abstract 1
- JUZYLCPPVHEVSV-LJQANCHMSA-N elvitegravir Chemical compound COC1=CC=2N([C@H](CO)C(C)C)C=C(C(O)=O)C(=O)C=2C=C1CC1=CC=CC(Cl)=C1F JUZYLCPPVHEVSV-LJQANCHMSA-N 0.000 abstract 1
- 229960003586 elvitegravir Drugs 0.000 abstract 1
- LDEKQSIMHVQZJK-CAQYMETFSA-N tenofovir alafenamide Chemical compound O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1 LDEKQSIMHVQZJK-CAQYMETFSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261594894P | 2012-02-03 | 2012-02-03 | |
| US201261618411P | 2012-03-30 | 2012-03-30 | |
| US201261624676P | 2012-04-16 | 2012-04-16 | |
| US201261692392P | 2012-08-23 | 2012-08-23 | |
| US201261737493P | 2012-12-14 | 2012-12-14 | |
| PCT/US2013/024438 WO2013116720A1 (en) | 2012-02-03 | 2013-02-01 | Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MD20140091A2 true MD20140091A2 (ro) | 2015-01-31 |
Family
ID=47722563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDA20140091A MD20140091A2 (ro) | 2012-02-03 | 2013-02-01 | Terapie combinată cuprinzând hemifumarat tenofovir alafenamidă şi cobicistat pentru utilizare în tratamentul infecţiilor virale |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20150105350A1 (https=) |
| EP (1) | EP2809323A1 (https=) |
| JP (1) | JP6059255B2 (https=) |
| KR (1) | KR20140119177A (https=) |
| CN (1) | CN104105484A (https=) |
| AU (3) | AU2013204727A1 (https=) |
| BR (1) | BR112014018918A8 (https=) |
| CA (1) | CA2863662A1 (https=) |
| EA (1) | EA026138B1 (https=) |
| HK (2) | HK1202801A1 (https=) |
| IL (1) | IL233874A0 (https=) |
| MD (1) | MD20140091A2 (https=) |
| MX (1) | MX2014009172A (https=) |
| NZ (1) | NZ629896A (https=) |
| WO (2) | WO2013116730A1 (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009008935A (es) | 2007-02-23 | 2009-11-02 | Gilead Sciences Inc | Moduladores de las propiedades farmacocineticas de productos terapeuticos. |
| RS53347B (sr) | 2008-12-09 | 2014-10-31 | Gilead Sciences, Inc. | Modulatori toll-sličnih receptora |
| ES2608871T5 (es) | 2011-08-16 | 2024-04-04 | Gilead Sciences Inc | Alafenamide hemifumarate de tenofovir |
| CN103665043B (zh) | 2012-08-30 | 2017-11-10 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药及其在医药上的应用 |
| HK1220390A1 (zh) * | 2013-08-29 | 2017-05-05 | Teva Pharmaceutical Industries Ltd. | 包括恩曲他滨，替诺福韦，达芦那韦和利托那韦的单位剂型以及包含达芦那韦和利托那韦的单体片剂 |
| IN2013CH05455A (https=) * | 2013-11-27 | 2015-08-07 | Laurus Labs Private Ltd | |
| WO2015120057A1 (en) * | 2014-02-05 | 2015-08-13 | Gilead Sciences, Inc. | Pharmaceutical combinations against co-infection with hiv and tuberculosis |
| CA2942877A1 (en) * | 2014-04-08 | 2015-10-15 | Nitzan SHAHAR | Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir |
| CN105518011B (zh) * | 2014-04-21 | 2018-07-27 | 四川海思科制药有限公司 | 氨基磷酸酯类衍生物制备方法及其中间体和中间体的制备方法 |
| US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| JP6522732B2 (ja) * | 2014-07-11 | 2019-05-29 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖを治療するためのトール様受容体の調節因子 |
| SG11201701520TA (en) | 2014-09-16 | 2017-04-27 | Gilead Sciences Inc | Solid forms of a toll-like receptor modulator |
| CN105237571B (zh) * | 2014-11-28 | 2018-03-09 | 成都苑东生物制药股份有限公司 | 9‑[(r)‑2‑[[(s)‑[[(s)‑1‑(异丙氧基羰基)乙基]氨基]苯氧基氧膦基]甲氧基]丙基]腺嘌呤的盐 |
| US20180338993A1 (en) * | 2014-12-04 | 2018-11-29 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| JP7381190B2 (ja) | 2014-12-26 | 2023-11-15 | エモリー・ユニバーシテイ | Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途 |
| AU2015373104B2 (en) * | 2015-01-03 | 2020-07-09 | Mylan Laboratories Limited | Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof |
| WO2016172342A1 (en) | 2015-04-21 | 2016-10-27 | Eiger Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising lonafarnib and ritonavir |
| CN104817593B (zh) * | 2015-04-27 | 2016-11-16 | 广州同隽医药科技有限公司 | 半富马酸替诺福韦艾拉酚胺关键中间体的合成工艺 |
| CA2921336A1 (en) * | 2015-06-30 | 2016-12-30 | Gilead Sciences, Inc. | Pharmaceutical formulations |
| PT4070788T (pt) * | 2015-06-30 | 2023-06-06 | Gilead Sciences Inc | Formulações farmacêuticas |
| US9598459B2 (en) | 2015-08-03 | 2017-03-21 | Pop Test Oncology Llc | Pharmaceutical compositions and methods |
| CN105153231A (zh) * | 2015-08-28 | 2015-12-16 | 浙江车头制药股份有限公司 | 一种一苯基pmpa的制备方法 |
| WO2017083304A1 (en) * | 2015-11-09 | 2017-05-18 | Gilead Sciences, Inc. | Therapeutic compositions for treatment of human immunodeficiency virus |
| US20170232020A1 (en) * | 2016-02-12 | 2017-08-17 | Cipla Limited | Pharmaceutical compositions |
| CN107179355B (zh) * | 2016-03-11 | 2021-08-10 | 广东东阳光药业有限公司 | 一种分离检测替诺福韦艾拉酚胺及其有关物质的方法 |
| EP3503895B1 (en) * | 2016-08-25 | 2021-09-15 | Merck Sharp & Dohme Corp. | Antiviral prodrugs of tenofovir |
| CN108070003A (zh) * | 2016-12-02 | 2018-05-25 | 上海博志研新药物技术有限公司 | 替诺福韦艾拉酚胺半反丁烯二酸盐晶型及制备方法和应用 |
| RU2659388C1 (ru) | 2017-02-28 | 2018-07-02 | Васильевич Иващенко Александр | Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение |
| RU2647576C1 (ru) * | 2017-02-28 | 2018-03-16 | Васильевич Иващенко Александр | Циклобутил (S)-2-[[[(R)-2-(6-аминопурин-9-ил)-1-метил-этокси]метил-фенокси-фосфорил]амино]-пропаноаты, способ их получения и применения |
| CN106928277A (zh) * | 2017-03-16 | 2017-07-07 | 江苏诚信药业有限公司 | 一种替诺福韦艾拉酚胺合成的工艺方法 |
| AU2018239257B2 (en) | 2017-03-20 | 2023-09-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HIV post-exposure prophylaxis |
| CN110769856A (zh) * | 2017-04-18 | 2020-02-07 | 希普拉有限公司 | 用于治疗逆转录病毒感染的组合疗法 |
| RU2659693C1 (ru) * | 2017-06-30 | 2018-07-03 | Общество с ограниченной ответственностью "Изварино Фарма" | Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции |
| EP3700573A1 (en) * | 2017-10-24 | 2020-09-02 | Gilead Sciences, Inc. | Methods of treating patients co-infected with a virus and tuberculosis |
| PT3706762T (pt) | 2017-12-07 | 2024-12-05 | Univ Emory | N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos |
| CN110305163A (zh) * | 2018-03-27 | 2019-10-08 | 北京济美堂医药研究有限公司 | 替诺福韦艾拉酚胺半富马酸盐的制备方法 |
| CN108484672A (zh) * | 2018-05-23 | 2018-09-04 | 中国药科大学制药有限公司 | 磷丙替诺福韦的手性拆分方法 |
| CN109081853A (zh) * | 2018-09-03 | 2018-12-25 | 南京正大天晴制药有限公司 | 一种磷丙替诺福韦有关物质的制备方法 |
| TWI810456B (zh) | 2019-05-22 | 2023-08-01 | 美商基利科學股份有限公司 | Tlr7調節化合物及hiv疫苗之組合 |
| EP3989956A1 (en) * | 2019-06-28 | 2022-05-04 | Anhui Ronghang Biotech Development Co., Ltd. | Compositions and methods for treatment of hepatitis b virus infection |
| AU2020318808A1 (en) | 2019-07-19 | 2022-02-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HIV pre-exposure prophylaxis |
| CN111606949A (zh) * | 2020-03-13 | 2020-09-01 | 浙江车头制药股份有限公司 | 一种磷丙替诺福韦杂质的制备方法 |
| CN111303209A (zh) * | 2020-03-21 | 2020-06-19 | 石家庄龙泽制药股份有限公司 | 一种丙酚替诺福韦降解杂质的制备方法 |
| WO2022118020A1 (en) * | 2020-12-02 | 2022-06-09 | Cipla Limited | Method of treating viral infection |
| WO2024196814A1 (en) | 2023-03-17 | 2024-09-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for treatment of age-related macular degeneration |
| EP4640214A1 (en) * | 2024-03-28 | 2025-10-29 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A tablet comprising tenofovir alafenamide monofumarate |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB453061A (en) | 1935-03-23 | 1936-09-04 | Charles Howard Twigg | Improvements in and relating to gas heated geysers and water heaters |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| US20020119443A1 (en) | 2000-07-21 | 2002-08-29 | Gilead Sciences, Inc. | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
| DE10153078A1 (de) | 2001-10-30 | 2003-05-22 | Degussa | Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen |
| DK1583542T3 (da) | 2003-01-14 | 2008-09-22 | Gilead Sciences Inc | Sammensætninger og fremgangsmåder til antiviral kombinationsterapi |
| MX2009008935A (es) * | 2007-02-23 | 2009-11-02 | Gilead Sciences Inc | Moduladores de las propiedades farmacocineticas de productos terapeuticos. |
| WO2009005693A1 (en) | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Novel hiv reverse transcriptase inhibitors |
| EP2393485B1 (en) * | 2009-02-06 | 2015-07-29 | Gilead Sciences, Inc. | Bilayer tablets comprising elvitegravir, cobicistat, emtricitabine and tenofovir |
| ES2608871T5 (es) * | 2011-08-16 | 2024-04-04 | Gilead Sciences Inc | Alafenamide hemifumarate de tenofovir |
-
2013
- 2013-02-01 AU AU2013204727A patent/AU2013204727A1/en not_active Abandoned
- 2013-02-01 JP JP2014555783A patent/JP6059255B2/ja active Active
- 2013-02-01 EP EP13704863.3A patent/EP2809323A1/en not_active Withdrawn
- 2013-02-01 AU AU2013204731A patent/AU2013204731C1/en active Active
- 2013-02-01 BR BR112014018918A patent/BR112014018918A8/pt not_active IP Right Cessation
- 2013-02-01 HK HK15103394.9A patent/HK1202801A1/xx unknown
- 2013-02-01 HK HK15105031.3A patent/HK1204914A1/xx unknown
- 2013-02-01 CN CN201380007670.XA patent/CN104105484A/zh active Pending
- 2013-02-01 WO PCT/US2013/024451 patent/WO2013116730A1/en not_active Ceased
- 2013-02-01 EA EA201491287A patent/EA026138B1/ru unknown
- 2013-02-01 KR KR20147024291A patent/KR20140119177A/ko not_active Withdrawn
- 2013-02-01 WO PCT/US2013/024438 patent/WO2013116720A1/en not_active Ceased
- 2013-02-01 CA CA 2863662 patent/CA2863662A1/en not_active Abandoned
- 2013-02-01 MD MDA20140091A patent/MD20140091A2/ro not_active Application Discontinuation
- 2013-02-01 MX MX2014009172A patent/MX2014009172A/es unknown
- 2013-02-01 US US14/376,116 patent/US20150105350A1/en not_active Abandoned
- 2013-02-01 NZ NZ629896A patent/NZ629896A/en unknown
-
2014
- 2014-07-30 IL IL233874A patent/IL233874A0/en unknown
-
2016
- 2016-06-02 AU AU2016203666A patent/AU2016203666A1/en not_active Abandoned
- 2016-10-03 US US15/284,105 patent/US20170056423A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013204731A1 (en) | 2013-08-22 |
| EA026138B1 (ru) | 2017-03-31 |
| NZ629896A (en) | 2016-03-31 |
| EA201491287A1 (ru) | 2015-04-30 |
| BR112014018918A2 (https=) | 2017-06-20 |
| BR112014018918A8 (pt) | 2017-07-11 |
| WO2013116720A1 (en) | 2013-08-08 |
| MX2014009172A (es) | 2014-08-27 |
| WO2013116730A1 (en) | 2013-08-08 |
| JP6059255B2 (ja) | 2017-01-11 |
| HK1202801A1 (en) | 2015-10-09 |
| HK1204914A1 (en) | 2015-12-11 |
| AU2013204731C1 (en) | 2017-08-31 |
| US20170056423A1 (en) | 2017-03-02 |
| JP2015505565A (ja) | 2015-02-23 |
| IL233874A0 (en) | 2014-09-30 |
| CA2863662A1 (en) | 2013-08-08 |
| KR20140119177A (ko) | 2014-10-08 |
| US20150105350A1 (en) | 2015-04-16 |
| AU2013204727A1 (en) | 2013-08-22 |
| AU2016203666A1 (en) | 2016-06-23 |
| EP2809323A1 (en) | 2014-12-10 |
| AU2013204731B2 (en) | 2016-03-03 |
| CN104105484A (zh) | 2014-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MD20140091A2 (ro) | Terapie combinată cuprinzând hemifumarat tenofovir alafenamidă şi cobicistat pentru utilizare în tratamentul infecţiilor virale | |
| MY179392A (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
| MD4508B1 (ro) | Hemifumarat de tenofovir alafenamidă şi utilizările sale medicale | |
| PH12015502780A1 (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
| PH12015500274B1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
| MY169159A (en) | Piperidino-pyrimidine derivatives for the treatment of viral infections | |
| MY167797A (en) | Macrocyclic purines for the treatment of viral infections | |
| PH12015500713A1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
| MY166557A (en) | Quinazoline derivatives for the treatment of viral infections and further diseases | |
| MX2013011411A (es) | Tratamiento para infeccion por el virus de hepatitis b solo o en combinacion con el virus de hepatitis delta y enfermedades hepaticas asociadas. | |
| UA81083U (ru) | Способ лечения больных острыми респираторными вирусными инфекциями |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA9A | Abandonment or withdrawal of application (patent for invention) |